BTG's TheraSphere IO Treatment Studied With HealthLoop Digital Patient-Engagement Platform

 

June 11, 2017—BTG International announced the results of a pilot study evaluating the effectiveness of a digital patient-engagement platform to educate, engage, and measure health-related quality of life in a patient group with primary hepatocellular carcinoma undergoing treatment with the company's TheraSphere yttrium-90 transarterial radioembolization therapy. The digital patient engagement platform is the IO Loop service powered by HealthLoop (HealthLoop Software Company).

The findings, which demonstrated sustained quality of life at regular intervals through 3 months following treatment, were presented at WCIO 2017, the annual World Conference on Interventional Oncology held June 8–11 in Boston, Massachusetts.

BTG stated that the HealthLoop data collection tool uses automated prompts to help patients better engage in their own care while measuring patient quality of life and satisfaction rates across the duration of their treatment.

HealthLoop uses automated delivery of digital patient-reported outcome surveys embedded within a continuous remote guidance experience. In the study, 71% of all patient-reported outcome surveys were completed and submitted by patients. Additionally, 87% of patients activated their accounts (mean overall engagement rate, 65%).

The multicenter study enrolled 41 patients on a digital patient engagement platform to guide them through their TheraSphere treatment (21 days pretreatment through 90 days posttreatment). Patients were surveyed at regular intervals (baseline, 2, 4, 8, and 12 weeks posttreatment). The timing of these questions was intended to address preservation of physical, functional, and symptom-related quality of life throughout the treatment and near-term follow-up period.

BTG reported that results delivered via the IO Loop showed stable quality of life and low side-effect concerns. 

In the announcement, the study's lead author, Riad Salem, MD, commented, “From these results we confirm several observations. First, the IO Loop service provides a powerful digital tool that delivers on several counts, bringing considerable benefits to patients and clinicians. Second, TheraSphere, a treatment for hepatocellular carcinoma that can be done as an outpatient procedure, is very well tolerated. Third, quality of life is maintained after TheraSphere, an outcome in cancer therapy that is extremely important when patients are ultimately selecting a treatment. Finally, relevant just-in-time information can be relayed from patients to physicians in a timely manner, with outcomes immediately accessible for patient and providers. Using this form of two-way communication improves patient care, quality, and overall satisfaction.” Dr. Salem is from Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Study investigator Edward Kim, MD, added, “This study shows that digital patient engagement platforms, delivered via services such as IO Loop, can educate and empower patients by automatically providing daily patient check-ins, education and guidance tools, and answers to common questions. By providing patients with relevant information at the right time, IO Loop helps to make sure clinician-patient interactions are as valuable and productive as possible.” Dr. Kim is Director of Interventional Oncology and associate professor of radiology and surgery at Mount Sinai Medical Center in New York, New York.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.